Bavarian Nordic A/S (BVNRY)

OTCMKTS · Delayed Price · Currency is USD
12.44
+0.13 (1.07%)
Aug 22, 2025, 2:36 PM EDT
1.07%
Market Cap2.89B
Revenue (ttm)1.02B
Net Income (ttm)223.97M
Shares Outn/a
EPS (ttm)2.82
PE Ratio12.91
Forward PE15.60
Dividendn/a
Ex-Dividend Daten/a
Volume796
Average Volume10,153
Open12.33
Previous Close12.31
Day's Range12.31 - 12.46
52-Week Range6.60 - 14.11
Beta1.12
RSI72.94
Earnings DateAug 22, 2025

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 1,605
Stock Exchange OTCMKTS
Ticker Symbol BVNRY
Full Company Profile

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.

Financial numbers in DKK Financial Statements

News

Bavarian Nordic beats revenue expectations, as launch of takeover bid nears

Bavarian Nordic , subject of a takeover offer valuing the vaccine maker at about 19 billion Danish crowns ($3 billion), reported a higher than expected revenue for the second quarter on Friday, citing...

10 hours ago - Reuters

Bavarian Nordic (BVNKF) Reports Strong Revenue Growth in 1H 2024

Bavarian Nordic (BVNKF) Reports Strong Revenue Growth in 1H 2024

12 hours ago - GuruFocus

Bavarian Nordic Announces First Half 2025 Results

COPENHAGEN, Denmark, August 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2025 and released its financial calenda...

15 hours ago - GlobeNewsWire

Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance

COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consi...

22 days ago - GlobeNewsWire

Consortium led by Nordic Capital, Permira to acquire Bavarian Nordic

Vaccine maker Bavarian Nordic said on Monday it had entered into an agreement with Innosera ApS, a newly formed company controlled by a consortium led by Nordic Capital and Permira, which is to make a...

25 days ago - Reuters

Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

25 days ago - GlobeNewsWire

Bavarian Nordic climbs after buyout offer

4 weeks ago - Seeking Alpha

Permira, Nordic in Takeover Talks for Vaccine Maker Bavarian

A consortium consisting of Nordic Capital and Permira is in talks for a potential takeover of Bavarian Nordic A/S, a Copenhagen-listed vaccine maker.

4 weeks ago - Financial Post

Bavarian Nordic in talks with Nordic Capital and Permira on potential takeover

Danish biotech Bavarian Nordic said on Thursday it is in discussions with a consortium of Nordic Capital and Permira regarding a potential takeover offer.

4 weeks ago - Reuters

Rumours of a Potential Takeover Offer for Bavarian Nordic A/S

COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of Nordi...

4 weeks ago - GlobeNewsWire

Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company's application for licensure of the single-dose, virus-like p...

4 weeks ago - GlobeNewsWire

Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country

COPENHAGEN, Denmark, July 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued over DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to a European countr...

6 weeks ago - GlobeNewsWire

Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women

COPENHAGEN, Denmark, June 26, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support approval and use of the MVA-BN® mpox/smallpo...

2 months ago - GlobeNewsWire

Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children

COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 3 clinical study of its single-dose, virus-like particle (VLP) chikungunya vaccine, CHIKV...

2 months ago - GlobeNewsWire

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manager...

3 months ago - GlobeNewsWire

Bavarian Nordic Announces Interim Results for the First Three Months of 2025

COPENHAGEN, Denmark , May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025.

3 months ago - GlobeNewsWire

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines

COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Pre...

3 months ago - GlobeNewsWire

Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom

COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the Uni...

4 months ago - GlobeNewsWire

Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP)

COPENHAGEN, Denmark, April 16, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACI...

4 months ago - GlobeNewsWire